GliaCure Highlighted in ADDF Top 5 Advances Report
The Alzheimer’s Drug Discovery Foundation (ADDF) recently reported on the top five Alzheimer’s research advances of 2016. Among these advances was the increasing evidence supporting a key role for neuroinflammation in the progress of Alzheimer’s disease. The article specifically referenced GliaCure’s Phase 1 trial in mild to moderate Alzheimer’s patients using GC021109, which targets inflammation. This trial was funded in part by the ADDF.
For the full article, go to: ADDF 2016 top five advances